Who
Richard H. Bagger
Director
Company insider
Files Form 4 as: Director, Tonix Pharmaceuticals Holding; Senior Vice President, Pfizer.
In numbers
- Trades disclosed
- 67
- Buys
- 2
- Sells
- 0
- Bought
- $34K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 31 Aug 2006
- Last trade
- 20 Aug 2026
- Last filed
- 24 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Aug 2026filed 24 Aug 2026 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Bought | $13K1,000 at $12.60 | filing |
| 20 Aug 2026filed 24 Aug 2026 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Bought | $13K1,000 at $12.60 | filing |
| 12 May 2026filed 14 May 2026 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,700 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,700 at $0.00 | filing |
| 13 May 2025filed 15 May 2025 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 5 Feb 2025filed 28 Feb 2025 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Code J | $00.02 at $0.20 | filing |
| 23 May 2024filed 24 May 2024 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —104,621 at $0.00 | filing |
| 8 May 2023filed 10 May 2023 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 9 May 2022filed 11 May 2022 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,131,500 at $0.00 | filing |
| 10 May 2021filed 12 May 2021 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —270,882 at $0.00 | filing |
| 13 Aug 2020filed 17 Aug 2020 | TNXP Tonix Pharmaceuticals HoldingBiotechnology | SEC FORM 4 Bought | $9,10010,000 at $0.91 | filing |
| 9 Jun 2020filed 11 Jun 2020 | TNXP Tonix Pharmaceuticals Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —68,750 at $0.00 | filing |
| 31 Dec 2008filed 5 Jan 2009 | PFE Pfizeroption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $97455 at $17.71 | filing |
| 15 Dec 2008filed 16 Dec 2008 | PFE Pfizeroption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $98159 at $16.63 | filing |
| 26 Nov 2008filed 1 Dec 2008 | PFE Pfizeroption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $1,02864 at $16.07 | filing |
| 14 Nov 2008filed 17 Nov 2008 | PFE Pfizeroption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $2,654163 at $16.28 | filing |
| 31 Oct 2008filed 3 Nov 2008 | PFE Pfizeroption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $99256 at $17.71 | filing |
| 15 Oct 2008filed 16 Oct 2008 | PFE Pfizeroption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $99261 at $16.27 | filing |
| 30 Sep 2008filed 1 Oct 2008 | PFE Pfizeroption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $99654 at $18.44 | filing |
| 15 Sep 2008filed 16 Sep 2008 | PFE Pfizeroption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $93952 at $18.05 | filing |
News
Tonix Pharmaceuticals (TNXP) Stock Price, News & AnalysisTNXP · 247wallst.com · 22 Oct 2026Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on PainTNXP · manilatimes.net · 19 Oct 2026Tonix Pharmaceuticals Sets 2027 Phase 1 Target For TNX-801 Vaccine CandidateTNXP · rttnews.com · 15 Oct 2026
0 headlines in the last 90 days name Richard H. Bagger; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.